Teva Pharmaceutical Industries (TEVA 0.57%) received some bad news last week after its oral multiple sclerosis drug laquinimod received a negative opinion by the EU's CHMP. In this video, Motley Fool health-care analyst Max Macaluso takes a look at what this decision means for Teva today, and where the company needs to strategically go from here following this decision.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.